Monday, April 06, 2015 8:53:44 AM
NeoStem to Present at Multiple April Conferences
New York, April 6, 2015 - NeoStem, Inc. (NASDAQ:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel cell-based personalized medicine therapies, announced today that the Company's management and experts will present at multiple conference in April.
HemOnc Today Melanoma and Cutaneous Malignancies
•Date and Time: Friday, April 10, 2015, 5:10 PM ET
•Venue: Sheraton New York Times Square Hotel, New York, New York
•Website: www.healio.com/meeting/hemonctodaymelanoma/home
•Presenter: Dr. Robert O. Dillman, Vice President, Oncology
•Poster: INTUS: Randomized Phase III Trial of Patient-specific Therapeutic Vaccine (NBS20) in Patients With Metastatic Melanoma
Crain's 'Business Of' Series: Life Sciences
•Date and Time: Wednesday, April 15, 2015, 8:30 AM - 10:00 AM ET
•Venue:John Jay College of Criminal Justice, New York, New York
•Website:http://www.crainsnewyork.com/events.../details/4/3256496
•Panelist: Dr. Robin L. Smith, Executive Chairman
•Topic:Life Sciences, Economic Diversification and Job Growth
Needham & Company's 14th Annual Healthcare Conference
•Date and Time: Wednesday, April 15, 2015, 3:00 PM ET
•Venue: The Westin Grand Central Hotel, New York, New York
•Website: ://www.needhamco.com/.../InstitutionalSa.../Conferences.aspx
•Presenter: Dr. David Mazzo, Chief Executive Officer
•Topic: Company Presentation
•Webcast:www.neostem.com/investors/investor-events/
American Association for Cancer Research Annual Meeting
•Date and Time: Wednesday, April 22, 2015, 8:00 AM ET
•Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania
•Website: www.aacr.org/Meetings/Pages/MeetingDetail.aspx...
•Presenter: Dr. Andrew N. Cornforth, Manufacturing Director
•Poster: Microarray analysis of melanoma autologous tumor cell lines used as the source of tumor associated antigens in patient-specific dendritic cell immunotherapy phase II trial in patients with metastatic melanoma
Interphex
•Date and Time: Wednesday, April 22, 2015, 2:00 PM ET
•Venue: Jacob Javits Center, New York, New York
•Website: www.interphex.com
•Presenter: Dr. Robert Preti, Chief Scientific Officer
•Topic: Development by Design: A Strategy to Support Commercial Success
Stem Cell Summit 2015
•Date and Time: Tuesday, April 28, 2015, 4:05 PM ET
•Venue: Hyatt Regency, Boston, Massachusetts
•Website: www.gtcbio.com/conferences/stem-cell-summit-agenda
•Presenter: Dr. Hans Keirstead, President, NeoStem Oncology
•Topic: Immunotherapy - Revolution in Cancer
Home - HemOnc Today Melanoma CME Meeting
You're invited to join more than 250 colleagues and...
healio.com
Recent LSTA News
- Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024 • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma • GlobeNewswire Inc. • 04/23/2024 11:30:00 AM
- Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma • GlobeNewswire Inc. • 04/09/2024 12:30:00 PM
- Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events • GlobeNewswire Inc. • 04/03/2024 12:30:00 PM
- Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma • GlobeNewswire Inc. • 03/21/2024 12:00:00 PM
- Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 09:05:00 PM
- Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Lisata Therapeutics to Present at BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico • GlobeNewswire Inc. • 01/18/2024 01:30:00 PM
- Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme • GlobeNewswire Inc. • 01/17/2024 01:00:00 PM
- Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma • GlobeNewswire Inc. • 12/12/2023 01:00:00 PM
- Lisata Therapeutics to Present at NobleCon19 Investor Conference • GlobeNewswire Inc. • 11/28/2023 09:05:00 PM
- Lisata Therapeutics Announces Participation in Upcoming Conferences in November • GlobeNewswire Inc. • 11/09/2023 09:05:00 PM
- Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/02/2023 08:05:00 PM
- Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time • GlobeNewswire Inc. • 10/26/2023 12:00:00 PM
- Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide • GlobeNewswire Inc. • 10/24/2023 12:00:00 PM
- Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer • GlobeNewswire Inc. • 10/17/2023 12:00:00 PM
- Lisata Therapeutics Announces Participation in Upcoming Conferences in October • GlobeNewswire Inc. • 09/28/2023 12:00:00 PM
- Lisata Therapeutics Announces Participation in InfoSec World 2023 • GlobeNewswire Inc. • 09/20/2023 12:00:00 PM
- Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors • GlobeNewswire Inc. • 09/12/2023 12:00:00 PM
- Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma • GlobeNewswire Inc. • 09/06/2023 12:00:00 PM
- Lisata Therapeutics Announces Participation in Upcoming Conferences in September • GlobeNewswire Inc. • 09/05/2023 12:00:00 PM
- Impilo Therapeutics Launches to Enable Nucleic Acid-Based Medicines to Effectively Treat Solid Tumor Cancers • PR Newswire (US) • 08/15/2023 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM